文献一覧: Masaru Mimura (著者)

100 0 0 0 OA Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-Observation)

著者: Shin Takayama Tetsuhiro Yoshino Sayaka Koizumi Yasuhito Irie Tomoko Suzuki Susumu Fujii Rie Katori Mosaburo Kainuma Seiichi Kobayashi Tatsuya Nogami Kenichi Yokota Mayuko Yamazaki Satoko Minakawa Shigeki Chiba Norio Suda Yoshinobu Nakada Tatsuya Ishige Hirofumi Maehara Yutaka Tanaka Mahiko Nagase Akihiko Kashio Kazuhisa Komatsu Makoto Nojiri Osamu Shimooki Kayo Nakamoto Ryutaro Arita Rie Ono Natsumi Saito Akiko Kikuchi Minoru Ohsawa Hajime Nakae Tadamichi Mitsuma Masaru Mimura Tadashi Ishii Kotaro Nochioka Shih-Wei Chiu Takuhiro Yamaguchi Takao Namiki Akito Hisanaga Kazuo Mitani Takashi Ito
出版者: The Japanese Society of Internal Medicine
雑誌: Internal Medicine (ISSN:09182918)
巻号頁・発行日: pp.0027-22, (Released:2022-11-02)
参考文献数: 41
被引用文献数: 3

Objective Patients in whom coronavirus disease 2019 (COVID-19) was suspected or confirmed between January 1, 2020, and October 31, 2021, were enrolled from Japanese hospitals in this multicenter, retrospective, observational study. Methods Data on the treatment administered (including conventional and Kampo medicine) and changes in common cold-like symptoms (such as fever, cough, sputum, dyspnea, fatigue, and diarrhea) were collected from their medical records. The primary outcome was the number of days without a fever (with a body temperature <37 °C). The secondary outcomes were symptomatic relief and the worsening of illness, defined as the presence of a condition requiring oxygen inhalation. The outcomes of patients treated with and without Kampo medicine were compared. Patients We enrolled 962 patients, among whom 528 received conventional and Kampo treatment (Kampo group) and 434 received conventional treatment (non-Kampo group). Results Overall, after adjusting for the staging of COVID-19 and risk factors, there were no significant between-group differences in the symptoms or number of days being afebrile. After performing propensity score matching and restricting the included cases to those with confirmed COVID-19 who did not receive steroid administration and initiated treatment within 4 days from the onset, the risk of illness worsening was significantly lower in the Kampo group than in the non-Kampo group (odds ratio=0.113, 95% confidence interval: 0.014-0.928, p=0.0424). Conclusion Early Kampo treatment may suppress illness worsening risk in COVID-19 cases without steroid use. Further randomized controlled studies are needed to confirm the clinical benefit of Kampo medicine for COVID-19.

2023-12-02 21:21:23
100 + 170 Twitter

5 0 0 0 OA Midlife Intakes of the Isoflavone Genistein and Soy and the Risk of Late-life Cognitive Impairment: The JPHC Saku Mental Health Study

著者: Thomas Svensson Norie Sawada Masaru Mimura Shoko Nozaki Ryo Shikimoto Shoichiro Tsugane
出版者: Japan Epidemiological Association
雑誌: Journal of Epidemiology (ISSN:09175040)
巻号頁・発行日: pp.JE20210199, (Released:2021-12-18)
参考文献数: 39
被引用文献数: 2

Background: The number of people with cognitive impairment, including dementia, in the world is steadily increasing. Although the consumption of isoflavones and soy is associated with a reduced risk of cardiovascular disease, it might also be associated with cognitive impairment. The low number of studies investigating the association between soy/isoflavone intake and cognitive function warrant additional research.Methods: The Japan Public Health Center-based prospective (JPHC) Study is a large population-based cohort. Midlife dietary intake of soy and the isoflavone genistein was assessed on two occasions: in the years 1995 and 2000. In 2014–2015, 1,299 participants from Nagano prefecture completed a mental health screening. Of these, a total of 1,036 participants were included in analyses. Logistic regression was used to determine Odds Ratios (OR) and 95% Confidence Intervals (CI) for the association between midlife energy-adjusted genistein and soy food intake and cognitive impairment.Results: There were 392 cases of cognitive impairment (346 cases of MCI and 46 cases of dementia). Compared to the lowest dietary quartile of energy-adjusted genistein intake, the highest quartile was significantly associated with cognitive impairment (OR = 1.51; 95% CI, 1.02–2.24; P for trend = 0.03) in the final multivariable analysis.Conclusion: High midlife intake of the isoflavone genistein is associated with late-life cognitive impairment.

2023-05-27 22:25:29
5 + 0 Twitter

3 0 0 0 OA 表情・音声・日常生活活動の定量化から精神症状の客観的評価をリアルタイムで届けるデバイスの開発

著者: 岸本泰士郎吉村道孝北沢桃子榊原康文江口洋子藤田卓仙三村將 Taishiro Kishimoto Michitaka Yoshimura Momoko Kitazawa Yasubumi Sakakibara Yoko Eguchi Takanori Fujita Masaru Mimura
雑誌: SIG-AIMED = SIG-AIMED
巻号頁・発行日: vol.001, 2015-09-29

Most of the severity ratings are assessed through interview with patients in psychiatric filed. Such severity ratings sometimes lack objectivity that can lead to the delay/misjudgment of the treatment initiation/switch. A new technology which enables us to objectively quantify patients’ severity is needed. We here aim to develop a new device that analyzes patients’ facial expression, voice, and daily activities, and provides us with objective severity evaluation using machine learning technology. This study project was accepted by Japan Agency for Medical Research and Development (AMED) and will launch this year. The background of the study purpose and methods will be presented.

http://id.nii.ac.jp/1004/00000682/

2 0 0 0 OA Midlife Intakes of the Isoflavone Genistein and Soy and the Risk of Late-life Cognitive Impairment: The JPHC Saku Mental Health Study

著者: Thomas Svensson Norie Sawada Masaru Mimura Shoko Nozaki Ryo Shikimoto Shoichiro Tsugane
出版者: Japan Epidemiological Association
雑誌: Journal of Epidemiology (ISSN:09175040)
巻号頁・発行日: vol.33, no.7, pp.342-349, 2023-07-05 (Released:2023-07-05)
参考文献数: 39
被引用文献数: 2

2023-07-15 21:50:01
2 + 2 Twitter

1 0 0 0 OA Semiological Differences between Late-life Schizophrenia andSenile Dementia

著者: Min-Ho Song Hidemichi Hamada Masaru Mimura
出版者: The Keio Journal of Medicine
雑誌: The Keio Journal of Medicine (ISSN:00229717)
巻号頁・発行日: vol.63, no.2, pp.34-38, 2014 (Released:2014-06-25)
参考文献数: 23
被引用文献数: 1

It is sometimes difficult to distinguish late-life schizophrenia from senile dementia because elderly patients with schizophrenia can present in chronic remission and show gradual cognitive decline with aging. We aimed to elucidate the semiological characteristics of late-life chronic schizophrenia. Three patients aged between 60 and 66 years who were admitted to our hospital were included in this study. Detailed history taking and psychiatric interviews were performed and reviewed in the light of psychopathological semiology. Although the three patients with late-life schizophrenia showed significant cognitive decline on the Hasegawa dementia rating scale and their negative symptoms mimicked dementia, the following psychopathological characteristics clearly differentiated them from patients with senile dementia: (1) a shift of temporal organization toward the future with intact memory, (2) hypersensitivity, (3) ambivalent personal relationships, (4) systematic bodily delusions, and (5) an ante festum mindset. Identifying such clinical features of patients with late-life schizophrenia could be important for developing more effective pharmacotherapy and for providing appropriate psychotherapy.

2014-07-30 23:28:43
1 + 0 Twitter